Abarelix

We are Abarelix CAS:183552-38-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Abarelix
CAS.NO:183552-38-7
Synonyms:Abarelix
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 1688.4±65.0 °C at 760 mmHg
Molecular Formula C72H95ClN14O14
Molecular Weight 1416.063
Flash Point 974.9±34.3 °C
Vapour Pressure 0.0±0.3 mmHg at 25°C
Index of Refraction 1.601
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Abarelix is a synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It directly and competitively binds and blocks the gonadotropin releasing hormone receptors in the anterior pituitary, which inhibits the secretion and release of the luteinizing hormone (LH) and follicle stimulating hormone (FSH). For men, the inhibition of LH secretion prevents the release of testosterone. Therefore, it can relieve symptoms associated with prostate hypertrophy or prostate cancer.

Abarelix


Related News: It’s the first confirmed Wuhan coronavirus death from outside of mainland China, and brings the total toll to 305.Ácido N-Boc-L-glutámico 5-ciclohexil éster CAS:73821-97-3 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.3-Bromo-5-Chloro-2-Fluoropyridine CAS:884494-87-5 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.[[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]methyl]-triphenylphosphonium bromide CAS:154057-58-6 In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.At present, Linhai, Zhejiang Province, has established a national chemical raw material base in Zhejiang Province, which is the earliest and largest gathering area of ??domestic chemical raw material medicines and pharmaceutical intermediate industries.

Related Products
Product Name
1,3-Dihydroxyacetone Dimer Cas:62147-49-3 View Details
CAS:358-67-8 3,3,3-Trifluoropropylmethyldimethoxysilicon View Details
NAROACTY CL-140 Cas:68439-51-0 View Details
5-Chloro-2-fluoropyridine manufacturer 2,4,6-Trifluorobenzonitrile manufacturer 4-(TRIFLUOROMETHOXY)BENZOYL CHLORIDE manufacturer [3-(Dimethylamino)propyl]triphenylphosphonium bromide hydrobromide manufacturer Ethyl cyanoglyoxylate-2-oxime manufacturer